[go: up one dir, main page]

WO2009031682A1 - ジベンゾ[b,e]オキセピン誘導体含有点眼剤 - Google Patents

ジベンゾ[b,e]オキセピン誘導体含有点眼剤 Download PDF

Info

Publication number
WO2009031682A1
WO2009031682A1 PCT/JP2008/066185 JP2008066185W WO2009031682A1 WO 2009031682 A1 WO2009031682 A1 WO 2009031682A1 JP 2008066185 W JP2008066185 W JP 2008066185W WO 2009031682 A1 WO2009031682 A1 WO 2009031682A1
Authority
WO
WIPO (PCT)
Prior art keywords
dibenzo
eye drop
salt
oxepin derivative
oxepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/066185
Other languages
English (en)
French (fr)
Inventor
Masashi Nakakura
Eikichi Ono
Kouji Murai
Tadafumi Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Priority to US12/676,888 priority Critical patent/US20100227917A1/en
Priority to CA2698651A priority patent/CA2698651A1/en
Priority to JP2009531305A priority patent/JP5307015B2/ja
Priority to EP08829949A priority patent/EP2189157A4/en
Publication of WO2009031682A1 publication Critical patent/WO2009031682A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

　ジベンゾ[b,e]オキセピン誘導体またはその塩の濃度を高濃度にすることができる組成の点眼剤または局所投与用製剤、あるいは目のアレルギー性障害もしくは炎症性障害を治療するためまたは鼻のアレルギー性障害もしくは炎症性障害を治療するために有効な組成のジベンゾ[b,e]オキセピン誘導体またはその塩を含有する点眼剤または局所投与用製剤を提供すること等を目的とし、ジベンゾ[b,e]オキセピン誘導体またはその塩、および多価の弱酸、酸性アミノ酸もしくはそのアミド、塩基性アミノ酸もしくはそのアミドまたはそれらの塩を含有する点眼剤等を提供する。  
PCT/JP2008/066185 2007-09-06 2008-09-08 ジベンゾ[b,e]オキセピン誘導体含有点眼剤 Ceased WO2009031682A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/676,888 US20100227917A1 (en) 2007-09-06 2008-09-08 EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE
CA2698651A CA2698651A1 (en) 2007-09-06 2008-09-08 Eye drop containing dibenz [b,e] oxepin derivative
JP2009531305A JP5307015B2 (ja) 2007-09-06 2008-09-08 ジベンゾ［ｂ，ｅ］オキセピン誘導体含有点眼剤
EP08829949A EP2189157A4 (en) 2007-09-06 2008-09-08 EYE DROPPING WITH DIBENZO [b, e] OXEPINE DERIVATIVE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007231302 2007-09-06
JP2007-231302 2007-09-06
JP2008-106245 2008-04-15
JP2008106245 2008-04-15

Publications (1)

Publication Number Publication Date
WO2009031682A1 true WO2009031682A1 (ja) 2009-03-12

Family

ID=40428993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066185 Ceased WO2009031682A1 (ja) 2007-09-06 2008-09-08 ジベンゾ[b,e]オキセピン誘導体含有点眼剤

Country Status (5)

Country Link
US (1) US20100227917A1 (ja)
EP (1) EP2189157A4 (ja)
JP (1) JP5307015B2 (ja)
CA (1) CA2698651A1 (ja)
WO (1) WO2009031682A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535451A (ja) * 2010-07-21 2013-09-12 アルコン リサーチ， リミテッド 増強された溶解度特徴を有する薬学的組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2493823C1 (ru) * 2012-09-19 2013-09-27 Общество с ограниченной ответственностью "Инновационная фирма "МАРК" (ООО "Инновационная фирма "МАРК") Глазные капли, обладающие противоинфекционным, противовоспалительным и противоаллергическим действием
CA2929074A1 (en) * 2013-10-31 2015-05-07 Nephron Pharmaceuticals Corporation Formulation of olopatadine
EP3037094A1 (en) * 2014-12-23 2016-06-29 Poifa Warszawa SA Ophthalmic pharmaceutical composition
CN107847604B (zh) * 2015-10-25 2020-11-10 艾威药业(珠海)有限公司 眼用原位凝胶处方

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
JP2004536096A (ja) 2001-06-27 2004-12-02 アルコン，インコーポレイテッド 局所投与のためのオロパタジン処方物
WO2005102313A1 (ja) * 2004-04-21 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. 慢性副鼻腔炎の予防および／または治療剤
WO2006009093A1 (ja) * 2004-07-16 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. 睡眠障害の予防および／または治療剤
JP2006508138A (ja) * 2002-11-12 2006-03-09 アルコン，インコーポレイテッド アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1050304A1 (en) * 1998-11-16 2000-11-08 Rohto Pharmaceutical Co., Ltd. Liquid ophthalmic preparations
US7977376B2 (en) * 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
WO2008093358A2 (en) * 2007-01-29 2008-08-07 Sun Pharmaceutical Industries Limited Aqueous topical solution containing olopatadine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
US5116863A (en) 1986-03-03 1992-05-26 Kyowa Hakko Kogyo Co., Ltd. Dibenz[b,e]oxepin derivative and pharmaceutical compositions thereof
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
JPH09510235A (ja) 1995-06-06 1997-10-14 アルコン ラボラトリーズ， インコーポレイテッド アレルギー性眼疾患を処置するためのドキセピン誘導体を含有する局所的眼科用処方物
JP2004536096A (ja) 2001-06-27 2004-12-02 アルコン，インコーポレイテッド 局所投与のためのオロパタジン処方物
US6995186B2 (en) 2001-06-27 2006-02-07 Alcon, Inc. Olopatadine formulations for topical administration
JP2006508138A (ja) * 2002-11-12 2006-03-09 アルコン，インコーポレイテッド アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用
WO2005102313A1 (ja) * 2004-04-21 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. 慢性副鼻腔炎の予防および／または治療剤
WO2006009093A1 (ja) * 2004-07-16 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. 睡眠障害の予防および／または治療剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TAMURA T; SATO H; MIKI I; SUZUKI K; OHMORI K; KARASAWA A: "Effects of orally administered olopatadine hydrochloride on the ocular allergic reaction in rats", ALLERGOL INT., vol. 52, 2003, pages 77 - 83
TAMURA T; SATOH, MIKI I; SUZUKI K; OHMORI K; KARASAWA A: "Effects of orally administered olopatadine hydrochloride on the ocular allergic reaction in rats", ALLERGOL INT., vol. 52, 2003, pages 77 - 83

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535451A (ja) * 2010-07-21 2013-09-12 アルコン リサーチ， リミテッド 増強された溶解度特徴を有する薬学的組成物
JP2016169237A (ja) * 2010-07-21 2016-09-23 アルコン リサーチ， リミテッド 増強された溶解度特徴を有する薬学的組成物

Also Published As

Publication number Publication date
EP2189157A4 (en) 2012-10-31
US20100227917A1 (en) 2010-09-09
EP2189157A1 (en) 2010-05-26
CA2698651A1 (en) 2009-03-12
JPWO2009031682A1 (ja) 2010-12-16
JP5307015B2 (ja) 2013-10-02

Similar Documents

Publication Publication Date Title
BR112014027591A2 (pt) uso de pró-fungicidas de uk-2a para controle de ferrugem de soja
EA201070001A1 (ru) Водная композиция, содержащая соль, способ её получения и применения
WO2009031682A1 (ja) ジベンゾ[b,e]オキセピン誘導体含有点眼剤
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
BRPI0917013A2 (pt) métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
BRPI0716539A2 (pt) métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
CL2007002582A1 (es) Compuestos derivados de azolcarboxamidas; composicion herbicida; metodo de fabricacion de dichos compuestos; metodo para controlar vegetacion indeseable; y uso de dichos compuestos.
WO2008089268A3 (en) Methods and compositions for treating conditions associated with infection and/or inflammation
BR112012004057A2 (pt) formulação de concentrado em suspensão aquoso da formulação de concentrado em suspensão aquoso e metodo para controlar vegetação indesejada
WO2008045563A3 (en) Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
BRPI0916090A2 (pt) "método de controle para controlar um veículo usado fora de rodovias e método de controle para controlar uma composição de veículo
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0912928A2 (pt) "composto, e, composição isenta de pirogênio"
EP2303302A4 (en) FORMULATION AND METHOD FOR REDUCING OR PREVENTING SYMPTOMS ASSOCIATED WITH HEMIC ACID CRYSTALS
BRPI0912587A2 (pt) "composto, composição fungicida e método para o controle de doenças vegetais causadas por patógenos fúngicos de plantas"
BRPI0915439A2 (pt) composição tópica para o tratamento de ceratose actínica
FI20120287L (fi) Hartsihappoja sisältävä vesikoostumus käytettäväksi antimikrobisena hoitoaineena ja lisäaineena
BRPI1007680A2 (pt) "cristais com baixo e alto ponto de fusão; método de preparo dos mesmos; composição da suspensão e composição da suspensão aquosa"
BRPI0911814A2 (pt) "composto, composição fungicida e método para o controle do fungo fitopatogênico de culturas"
IL206450A (en) Use of a preparation that includes salt of o-acetylsalicylic acid and basic amino acid in the preparation of a drug for the prevention or treatment of viral infections
EP2045248A4 (en) PROCESS FOR PREVENTING COLORATION OF CATECHINS AND TOOTH COMPOSITION
BR112012018674A2 (pt) usos de pelo menos uma polietilenimina, e de uma suspensão, e, método para aumentar o ph de uma suspensão aquosa
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
BRPI0813159A8 (pt) Composição parasiticida veterinária, método para o tratamento ou controle de uma infecção ou infestação parasiticidas em um animal homeotérmico, e, uso de uma composição

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08829949

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009531305

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2698651

Country of ref document: CA

Ref document number: 12676888

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008829949

Country of ref document: EP